Xvivo Perfusion AB (publ) (XVIVO.ST)
SEK 465.0
(1.97%)
SEK 465.0
(1.97%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | 38.5 Million SEK | 66.11% |
| 2022 | 23.18 Million SEK | 232.01% |
| 2021 | 6.98 Million SEK | 120.35% |
| 2020 | -34.31 Million SEK | -709.14% |
| 2019 | 5.63 Million SEK | -59.76% |
| 2018 | 14 Million SEK | 97.02% |
| 2017 | 7.1 Million SEK | 159.91% |
| 2016 | 2.73 Million SEK | -62.09% |
| 2015 | 7.21 Million SEK | 7.83% |
| 2014 | 6.68 Million SEK | -37.92% |
| 2013 | 10.77 Million SEK | 4982.08% |
| 2012 | 212 Thousand SEK | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q1 | 18.99 Million SEK | 175.49% |
| 2024 Q2 | 33.42 Million SEK | 75.99% |
| 2024 Q3 | 20.47 Million SEK | -38.75% |
| 2023 Q4 | -25.16 Million SEK | -574.56% |
| 2023 Q3 | 5.3 Million SEK | 39.45% |
| 2023 Q1 | 11.2 Million SEK | 386.41% |
| 2023 Q2 | 3.8 Million SEK | -66.07% |
| 2023 FY | 38.5 Million SEK | 66.11% |
| 2022 Q1 | 1.49 Million SEK | 118.0% |
| 2022 FY | 23.18 Million SEK | 232.01% |
| 2022 Q4 | 2.3 Million SEK | 149.47% |
| 2022 Q3 | -4.65 Million SEK | 44.23% |
| 2022 Q2 | -8.35 Million SEK | -658.9% |
| 2021 Q2 | -9.35 Million SEK | -393.75% |
| 2021 Q4 | -8.3 Million SEK | -105.9% |
| 2021 Q3 | -4.03 Million SEK | 56.89% |
| 2021 FY | 6.98 Million SEK | 120.35% |
| 2021 Q1 | 3.18 Million SEK | 122.22% |
| 2020 FY | -34.31 Million SEK | -709.14% |
| 2020 Q2 | -12.7 Million SEK | -55356.52% |
| 2020 Q3 | -18.66 Million SEK | -46.83% |
| 2020 Q4 | -14.32 Million SEK | 23.22% |
| 2020 Q1 | 23 Thousand SEK | -98.56% |
| 2019 Q1 | -1.86 Million SEK | -130.45% |
| 2019 FY | 5.63 Million SEK | -59.76% |
| 2019 Q3 | 2.27 Million SEK | 18.04% |
| 2019 Q4 | 1.59 Million SEK | -29.91% |
| 2019 Q2 | 1.92 Million SEK | 203.6% |
| 2018 Q1 | 3.14 Million SEK | -33.55% |
| 2018 FY | 14 Million SEK | 97.02% |
| 2018 Q4 | 6.11 Million SEK | 728.46% |
| 2018 Q3 | 738 Thousand SEK | -81.55% |
| 2018 Q2 | 3.99 Million SEK | 26.99% |
| 2017 Q2 | 1.96 Million SEK | 15015.38% |
| 2017 Q1 | 13 Thousand SEK | -50.0% |
| 2017 FY | 7.1 Million SEK | 159.91% |
| 2017 Q4 | 4.73 Million SEK | 1118.25% |
| 2017 Q3 | 389 Thousand SEK | -80.2% |
| 2016 Q2 | 1.66 Million SEK | -6.31% |
| 2016 Q1 | 1.77 Million SEK | -59.59% |
| 2016 FY | 2.73 Million SEK | -62.09% |
| 2016 Q4 | 26 Thousand SEK | 103.55% |
| 2016 Q3 | -732 Thousand SEK | -143.99% |
| 2015 Q2 | 1.49 Million SEK | 10086.67% |
| 2015 Q1 | -15 Thousand SEK | -105.02% |
| 2015 FY | 7.21 Million SEK | 7.83% |
| 2015 Q4 | 4.39 Million SEK | 229.46% |
| 2015 Q3 | 1.33 Million SEK | -10.95% |
| 2014 FY | 6.68 Million SEK | -37.92% |
| 2014 Q4 | 299 Thousand SEK | -86.79% |
| 2014 Q2 | 1.38 Million SEK | -49.31% |
| 2014 Q1 | 2.73 Million SEK | 4.62% |
| 2014 Q3 | 2.26 Million SEK | 63.04% |
| 2013 Q4 | 2.61 Million SEK | -2.79% |
| 2013 Q2 | 2 Million SEK | -42.14% |
| 2013 FY | 10.77 Million SEK | 4982.08% |
| 2013 Q1 | 3.46 Million SEK | 1533.02% |
| 2013 Q3 | 2.69 Million SEK | 34.4% |
| 2012 Q4 | 212 Thousand SEK | 0.0% |
| 2012 FY | 212 Thousand SEK | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| Acarix AB (publ) | -77.55 Million SEK | 149.651% |
| ADDvise Group AB (publ) | 300.6 Million SEK | 87.19% |
| ADDvise Group AB (publ) | 300.6 Million SEK | 87.19% |
| Arcoma AB | 4.66 Million SEK | -726.309% |
| Bactiguard Holding AB (publ) | -131.93 Million SEK | 129.186% |
| BICO Group AB (publ) | -618.3 Million SEK | 106.228% |
| Boule Diagnostics AB (publ) | 39.27 Million SEK | 1.946% |
| CellaVision AB (publ) | 167.05 Million SEK | 76.95% |
| Clinical Laserthermia Systems AB (publ) | -65.93 Million SEK | 158.402% |
| Chordate Medical Holding AB (publ) | -29.57 Million SEK | 230.213% |
| C-Rad AB (publ) | 44.24 Million SEK | 12.969% |
| Duearity AB (publ) | -25.76 Million SEK | 249.462% |
| Dignitana AB (publ) | -15.02 Million SEK | 356.262% |
| Episurf Medical AB (publ) | -94.8 Million SEK | 140.618% |
| Getinge AB (publ) | 3.81 Billion SEK | 98.99% |
| Scandinavian Real Heart AB (Publ) | -68.44 Million SEK | 156.258% |
| Iconovo AB (publ) | -45.77 Million SEK | 184.117% |
| Integrum AB (publ) | 6.51 Million SEK | -491.277% |
| Luxbright AB (publ) | -25.8 Million SEK | 249.222% |
| Mentice AB (publ) | -679 Thousand SEK | 5770.987% |
| OssDsign AB (publ) | -91.95 Million SEK | 141.874% |
| Paxman AB (publ) | 12.61 Million SEK | -205.143% |
| Promimic AB (publ) | -9.11 Million SEK | 522.308% |
| Qlife Holding AB (publ) | -168.69 Million SEK | 122.826% |
| SciBase Holding AB (publ) | -53.93 Million SEK | 171.388% |
| ScandiDos AB (publ) | -13.48 Million SEK | 385.589% |
| Sectra AB (publ) | 518.49 Million SEK | 92.573% |
| Sedana Medical AB (publ) | -65.54 Million SEK | 158.746% |
| Senzime AB (publ) | -133.74 Million SEK | 128.791% |
| SpectraCure AB (publ) | -21.35 Million SEK | 280.348% |
| Stille AB | 44.95 Million SEK | 14.34% |
| Vitrolife AB (publ) | -3.58 Billion SEK | 101.073% |